REGENXBIO的RGX-121遭FDA临床暂停，近期不再重交BLA

----- 0001193125-26-363786-index-headers.html -----
<SEC-DOCUMENT>0001193125-26-363786-index.html : 20260824
<SEC-HEADER>0001193125-26-363786.hdr.sgml : 20260824
<ACCEPTANCE-DATETIME>20260824172014
ACCESSION NUMBER: 0001193125-26-363786
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 11
CONFORMED PERIOD OF REPORT: 20260824
ITEM INFORMATION: Regulation FD Disclosure
ITEM INFORMATION: Other Events
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260824
DATE AS OF CHANGE: 20260824
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENXBIO Inc.
CENTRAL INDEX KEY: 0001590877
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
EIN: 471851754
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37553
FILM NUMBER: 261311621
BUSINESS ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-552-8181
MAIL ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: REGENXBIO, Inc.
DATE OF NAME CHANGE: 20150116
FORMER COMPANY:
FORMER CONFORMED NAME: ReGenX Biosciences, LLC
DATE OF NAME CHANGE: 20131101
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rgnx-20260824.htm
<DESCRIPTION>8-K
<TEXT>
Document 1 - file: rgnx-20260824.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rgnx-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
Document 2 - file: rgnx-ex99_1.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img101737798_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 3 - file: img101737798_0.jpg
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>rgnx-20260824.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
Document 4 - file: rgnx-20260824.xsd
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 6 - file: R1.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 7 - file: report.css
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 8 - file: Show.js
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 10 - file: FilingSummary.html
Document 10 - RAW XML: FilingSummary.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 12 - file: MetaLinks.json
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001193125-26-363786-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 13 - file: 0001193125-26-363786-xbrl.zip
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>rgnx-20260824_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 14 - file: rgnx-20260824_htm.html
Document 14 - RAW XML: rgnx-20260824_htm.xml
</DOCUMENT>
</SEC-DOCUMENT>

----- 0001193125-26-363786.txt -----
0001193125-26-363786.txt : 20260824
0001193125-26-363786.hdr.sgml : 20260824
20260824172014
ACCESSION NUMBER: 0001193125-26-363786
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 11
CONFORMED PERIOD OF REPORT: 20260824
ITEM INFORMATION: Regulation FD Disclosure
ITEM INFORMATION: Other Events
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260824
DATE AS OF CHANGE: 20260824
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENXBIO Inc.
CENTRAL INDEX KEY: 0001590877
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
EIN: 471851754
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37553
FILM NUMBER: 261311621
BUSINESS ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-552-8181
MAIL ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: REGENXBIO, Inc.
DATE OF NAME CHANGE: 20150116
FORMER COMPANY:
FORMER CONFORMED NAME: ReGenX Biosciences, LLC
DATE OF NAME CHANGE: 20131101
8-K
1
rgnx-20260824.htm
8-K
8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 24, 2026
REGENXBIO Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-37553
47-1851754
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
9804 Medical Center Drive
Rockville
,
Maryland
20850
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code:
(
240
)
552-8181
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
RGNX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 7.01 Regulation FD Disclosure.
On August 24, 2026, REGENXBIO Inc. (the “Company”) announced that it received communication from the U.S. Food and Drug Administration (“FDA”) that the Company’s Investigational New Drug application for its Phase I/II/III trial of RGX-121 for Mucopolysaccharidosis type II (“MPS II”), also known as Hunter Syndrome, was placed on clinical hold and that the Company does not expect to resubmit the RGX-121 Biologics License Application (“BLA”) in the near term. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in Item 7.01 of this Current Report on Form 8‑K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 8.01. Other Events.
On August 24, 2026, the Company announced that it received communication from the FDA that the Company’s Investigational New Drug application for its Phase I/II/III trial of RGX-121 for MPS II was placed on clinical hold and that the Company does not expect to resubmit the RGX-121 BLA in the near term.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press release dated August 24, 2026.
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGENXBIO Inc.
Date:
August 24, 2026
By:
/s/ Patrick J. Christmas II
Patrick J. Christmas II
Executive Vice President, Chief Strategy & Legal Officer
EX-99.1
2
rgnx-ex99_1.htm
EX-99.1
EX-99.1
EXHIBIT 99.1
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
ROCKVILLE, Md., August 24, 2026 – REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. The U.S. Food and Drug Administration (FDA) placed a clinical hold on RGX-121 following the discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE
®
study; REGENXBIO does not expect to resubmit the RGX-121 Biologics License Application (BLA) in the near term.
“We believe these findings are unique and limited to our Hunter Syndrome program, and require longer-term follow-up and additional data analysis to assess the benefit-risk profile of RGX-121,” said Curran Simpson, President and CEO of REGENXBIO. “We remain focused on our Duchenne and retinal disease candidates, which utilize a different capsid and routes of administration, with near-term catalysts that are on track, including the planned submission of the Duchenne BLA this quarter and the wet AMD topline pivotal data announcement in the fourth quarter.”
All five participants continue to do well clinically and have demonstrated overall stability to improvement on neurocognitive and neurobehavioral assessments. The findings were identified through an expanded MRI monitoring plan, implemented by REGENXBIO a few months ago, following the clinical hold related to RGX-111. The enhanced monitoring included both brain and spine MRI and identified asymptomatic findings of either a small nodule or a small cystic mass in spine MRIs of five participants who received intracisternal or intraventricular RGX-121 approximately three to six years ago. Investigators deemed these findings to be nonserious and radiologists believe they are likely benign. There is no clinical or pathological evidence to confirm the nature or causation of the spine MRI findings. No brain nodules or masses were identified on any brain MRIs.
Because spine MRI is not normally conducted for MPS in clinical practice or trials, the underlying prevalence and clinical significance of these types of asymptomatic findings in this patient population is unknown. Investigators plan to continue to observe these patients with periodic imaging only.
“Boys with neuronopathic MPS II experience a multitude of neurodevelopmental and systemic effects. While imaging natural history is limited for this ultra-rare disease, I believe that asymptomatic, likely benign findings like these may be inherent to the impact of Hunter Syndrome throughout the body,” said Roberto Giugliani, M.D., Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil. “I am pleased that these patients are doing well and remain asymptomatic.”
The Company and its partner NS Pharma are evaluating additional patient imaging and longer term follow up data, and will incorporate FDA feedback, including the full clinical hold letter once received, into next steps for RGX-121.
About Mucopolysaccharidosis Type II (MPS II)
MPS II, or Hunter Syndrome, is a rare, X-linked recessive disease caused by a deficiency in the lysosomal enzyme I2S leading to an accumulation of glycosaminoglycans (GAGs), including heparan sulfate (HS) in tissues which ultimately results in cell, tissue, and organ dysfunction,
including in the CNS. Approximately 2,000 patients worldwide are diagnosed with MPS II, with more than 500 babies born annually around the world with the disease. The majority of MPS II patients have severe forms of the disease, with which early developmental milestones may be met, but developmental delay is readily apparent by 18 to 24 months. CSF HS is a key disease biomarker in MPS II patients. Among its quantified disaccharides, D2S6 has been shown to correlate with neurocognitive manifestations, highlighting its role as a clinically relevant biomarker of disease severity and therapeutic response.
About RGX-121 (clemidsogene lanparvovec)
RGX-121 is a one-time investigational gene therapy for the treatment of boys with MPS II, designed to deliver the iduronate-2-sulfatase (
IDS
) gene to the central nervous system (CNS). Delivery of the
IDS
gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 expressed protein is structurally identical to normal I2S.
RGX-121 has received Orphan Drug Product, Rare Pediatric Disease, Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations from the U.S. Food and Drug Administration and advanced therapy medicinal products (ATMP) classification from the European Medicines Agency.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and RGX-121 (clemidsogene lanparvovec) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA
®
. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit
www.REGENXBIO.com
.
FORWARD-LOOKING STATEMENTS
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, FDA’s review process, the success of clinical trials conducted by REGENXBIO, the ability to obtain and maintain regulatory approval of product candidates, and other factors, many of which are beyond the control of REGENXBIO.
Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2025, and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC's website at
WWW.SEC.GOV
. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Zolgensma
®
is a registered trademark of Novartis Gene Therapies. All other trademarks referenced herein are registered trademarks of REGENXBIO.
CONTACTS:
Dana Cormack
Corporate Communications
Dcormack@regenxbio.com
George E. MacDougall
Investor Relations
IR@regenxbio.com
GRAPHIC
3
img101737798_0.jpg
GRAPHIC
begin 644 img101737798_0.jpg
M_]C_X 02D9)1@ ! 0$ W #< #_VP!# (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P 1" !5 >8# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B
7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]^%.113L[
M$ZUY[\0/V@]!\ W_ -CD:XOKI6 DBM@&,><_>)( Z=,YY'&*THX>=67+!-OR
M.?$8JE0CS5)**\RO\;?VC-!^!AL5U);JXN-09O*M[1%:3:OWG.YE4 $@
(?M;_\ !3#PS\"OV2?$'Q"TE5N-
4KJI^:,(DD
MQVL-R0NH8,"!E?M)W.F_'36['4-+:XT_4+6(V[K?;1#,A;*@,K,%8,S9+87!
MY(V@'Y;_ ."LW[+&N>#?V!UU+;:WEU:^*+'6-0C@G4K!:);W5NK*#AG82W:!
MMFX!3GH&:OK
A*5*-=M2E))IZ75]?E8_-\TX@Q/-4]BDX)-II7MIH[][G
MYN_'C]I#QU^T[XNDU[QYXHU;Q-?;V:$7,O\ H]F&QN6&%<1PJ=JY6-5!(R
^MWZG[O_ +9'_!3:/X8PZ+I_@"/2
M]
6NDW&DZM
?#O1-)\,^,XK)'D&B:C:VBV['.P!K=OLS*LB%E+1N,C*@I\$/@EJ/
MQ#\56\U];W5CX=T^X1M2OGC95ACW E$)!W2N 0J]<\G"ABOY10R/*WELMG.V
MK>Z?2R_+N3B.*,[6;Q;O&FFM%LTGN_*VY^VUG=+=*K+_ !
),-C$H*:YNVU_3
MN>G Y%% .117DGTP4444 %%&:,T %%&:* "BBC- !11FC- !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%&:,T %%&:,T %%%% !1110 449HS
M0 4444 %%%% !1110 4444 %%%% !111F@ HHHH X;XN^+IO!?PZU*^AW?:(
M8PD;#&49V"*>01\I8'GKBODR:5YY&D9FD>0EB6.68GDDGUK!^.G_ 4 \<:Q
M_P %$;[X Q_#VXNO"]]]GLTU2+?YP=K:.Z%V6*[/)C<[77/W49@=WRUT5U93
M6%S);W$
_VG?@S\%/#?\ PC?C[QA-IOBC4+A;R*UL
M+1KZ:P6)2$$Z("8Q(LS8!() !_A(KVJT93E%4XMRO;1-NST=K7Z7U^[4^;C?
MV
4=+ZNRNMK_Y'SQ9_\$=_ _[1_C_5E\(^(-2\![E:[BTJXB&I6Z*9/F"3
M%D=54.JJK!CA
9_MI?LHV__ 27U_P/JWA75I/%'BS6I+V>VUS4+",6
MNCF VX3R("71KE6=CYDA8*K J@<*Z?0FM_M%^&=2_9WU+Q)\*_'"ZIK%U=1:
M9J:V\#VUUI-K*)29-C .IDDA1 ^!@$@')!'(_LI:7)^T=\>-!\'^,+6;QMX?
MUJ24WECJ4KSJFU&E,RLS;HV$B(Q9"I8#:
*/
M$5VGB:XTHRPQZ_+'MDBN5C9V*H/M,R%4^7>KG R /7/VA/[6LO ?A>/5&N?)
MN+F[FA64G,B!8=C-GDD%Y=N>S<<8KY[^)W[,GQ5\"_M5-I?A/0=4TO['?R?\
M(R^GQ^59V=EYF8]C*-BQJKCS,]6,A;
YLDJ!7S;J4WB(5:#4HN\FDT
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M^;#;O(FX C(W*,C(R,\BO)S+(L5@JL:5=6
Z>VS/2R[/J&*I2J4G=1W5M
M5\CT;=1O'^S^=?@XW_!PQ^T$[_\ ,B_^"I__ ([3?^(A;]H3/_,B_P#@ID_^
M/5Z5/A/%RCS)Q^]'#+BVA%VY9?
DWJO\ %7X-_P#$0K^T%_U(W_@I
MD_\ CU+_ ,1#7[07]WP+_P""F3_X]52X/Q25[Q^\C_6ZBW91E]S/WBE?Y=RT
MWS,?[U>0_L._&76/V@OV2? /C3Q!]E76/$6E1WEY]GC,<6]B<[5).!QZFOB'
M_@HU_P %V]6_9X^.?B#X>_#O0-)U*X\-R+:WFL7LYDB%SM#21)&O78S!&+,"
M'1QC'->1@
^NBL[-W['JXW/*&&H1JU'92M;35W5[6/U"HK\
M&V_X.%_V@BO_ #(__@KD_P#CM'_$0O\ M!?WO __ (*9?_CM>[_J5CO[OWGD
M_P"N>%[2^X_>%9L_Q4&4$_>K\'$_X.%_V@,_\R/_ ."J3_X[77?"7_@XX^*'
MA[7H6\7>&_#?B#3=X$ZV*/93(I(W%
C;6&1V/%?D'^TU_P78^.GPK_:/^(7A72U\&_P!E^&?$NI:39^?I
M;O)Y,%U)$F]A* 6V(,G R<\=J\' Y55Q-1TXV4H[INUM;'K8S.J>'IQG*[4M
MFE>^ES]L _%!?'I7X,_\1#'[07_4B_\ @KD_^.TW_B(9_:"_ZD?_ ,%,G_QZ
MO:_U1QG>/_@2/+_UPPW\LON/WC296]J0."./QK\'1_P<-?'X?]"/_P""J3_X
M[7Z2?\$
*O&RZ3_:FF^))M)@_L^W:WC\E;2TE&Y2S9;?,^
M3GIMXXR?-S#(ZN$I>UJ
AEN?TL5/V<$[V;U5MC[ CD\RC/^17Y
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M9]N8(O)2TM)1N4LWS;YGYSTQQQFO3J91B(818UI
+3SBC/%O"1
MOS)7>FG0^O6X6DSY2_WFKYG_ ."@OC[XO?"/PQ#XG^'_ /9>H:381$ZI8S6;
M2W$:@DF9"&&Y0OWE RNW=R,X^2_@I_P6-\:0?$>S_P"$VM]+N/#=P3%<-8V[
M1S6N2,2C+-N YRO!(.1R #\5C,^HX6JJ-:\7*UFUIKUN?HN4\&XW,<++%86T
ME&]TFKJWEN?J6C-N_O+WH$F6_I7.>!/B#IGQ#\+6>K:7>0WEGJ$2S13PN'C=
M& (8$>HKC?VGOVF_#O[,?P[NM
%A\KQ-7$+"QBW-NR26M[[6/5%E\QO]JI(SN2ORO^'/
M_!3GXZ?&SXGV^A^%=/\ #\EUJEP?L\/V2206L1.
CGG#N(RJ48XAI2DK\J=VO5=#H@^3_.DC=0O^U7QM_P56_X*:ZI_P $
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M;WVGWEZ]M=Y5M,^R12O
+2D[)W3
M5^VAW8'B3"XJ3C3E=I7:LT['TGO:BOFCQS^WYX>^$5YJ$GC6XM=+T&SF@M!J
M5@QNHUNY8WD2$[DPV](Y6#1E@IA7CMEC
-S]H[X,Z3\)O'GE_\)1X7TFS
MU2X4VMKJ%\EK-$)"P50I.2F0X#=,+@G(->4_M,MX+^'/PRU;P7XPM[CQ)>?$
M+0]ZR:7,C0V%NTH>"='.5D
[;NFWLK>;/._V8_P#@M%I?B_XM6.AZU\,[6U;7,V>F
M7%O?O=R"^?Y8$=651Y;N54GDJ64] :_-OQ-XJU#QOXGU#6M8O+C4-6U:X>ZN
M[F<[I)Y78LS,?4L>?RXQ7UMX9_9M\#_L,6_PU^-7C3Q!<>+M/OM1:^\/^&].
M@-K>7-U:3+N,\CY010R!=VT?.=H'RL<=!X2_X)V^'?\ @HY9^(OB-\%=6M_!
M]FNHLFI>%]9QNTF9SOS#,ORFW=3O4$94[E'W03]1E>88#+L0Z_*^222
NM._;1^&]G;QQW5KXB
M\06>@ZC;2J7BO+.ZG2&='4=0%
6'4IT(P0?LW?\$E;?\ 8>^$GCCXK:MX
MFL?$GC[P_P"']0ET7[#&#;:-*;5L3\Y+3*?,4'[H&".:^-SRV:_GOQKXZE/%
M1I8&3C&2M)IM7L^B^>Y_7GT>/"W!8JC/'8^$9RI_"FD[.U[M_(]R^(/[1OQM
M^%GBBWFU+QIXDAFOH4N+6Y\T&&YC95;
E==X/^.VD_MI> _%
M7PU\>0Z#X?\ ''C:R6PTCQK!9)#<-< ILAN74;RDK+Y;L#\Z2,I&"!7U)X^_
M9AT/X_?L8:&FH26]A?:7IL%S:WS@#[.ZQ*223_"P&&&>G/4"OS!NX9-&U:1(
M[B.1[64J)X)"58JV R-P<'&0>#WK\=HYUF&38RE5C4
*I/%'C"WT.X\3>*M'OM
M)T+28[D7EK
)Z)^W!\4/"6C2:7H_BJ;2]'
M:=YO[.MK2!;/<[;B3&4*L
,7^!?Q.U*/=I?B
MKP+:6;N@)2&]C=YI0>,+O6ZCV\Y;8^/NFO@]@ *_O;@&GALSRZ.,KQC*
^'
M&L>,/^"C/A/5M.M9)-/\(V=]?:I/@[((I+2>V0$]-S23IA>I 8C[IQ_0#MW0
M_A7Y!QS@2^9^
MW5X=_P"Q(M/_ $OOZ]L_X(&>%?AWKO[*WB:;Q=IO@^ZU"/Q=<)$^K06TDPB^
MQ66 ID!;;N+X XR6[YKQ+_@XZX_;G\._]B5:?^E]_7AO[(7_ 3;^+7[97@*
M_P#$G@%-);2=/U%]+G^TZE]E;SEBAD;"X.1LF7GUR.U?:X7 T:W#M.-6JJ:O
M>[[ZZ;H^$Q&(J4LXG*$.=W>B^6I^Y0^'GP(<_P#(%^&?X6ME_A5'7? 'P+.D
MS?\ $I^&,>X%23;62]>V<5^%O[77[$/Q6_8FN=)7QU9R6]KK2-]EOK.\:YM7
M=2
GV^K:PYCM1JE]]GMY
MI.H3<01O;/R@]3QWKGPO!:JT?K-/%
'V#:%'J=TNG%22#:B5O*(SU^3;7]1-TMC+X4F75%M6TMK4
MBZ%T%,#0[3O#[OEV[
*_'?]EO_ (-Z/B!X@^)&GS?$[4-'TGPK9SI+
M>6^G77VBYU"-3DQ*P $>X_*6.<#<1SBOUD_:2^']]\2_V
\/
M7VF68E?9&TLUO)&FYOX1N89/85X7&F9X?%5J-&A/FY%9R6W3_(]SA#+Z]&E4
MK3BTY;)[OK;T.0NO"GP")_Y!_P *?^_%A_A3!X6^ 9_YAOPI_P"_%A_A7Y$R
M?\&_?[1"?\PWPI_X.!_\10?^" /[1$G_ ##?"?\ X.!_\37+3RW".*OBE_7S
M-:F,Q'/_ ']W_ /UV/A;X _] WX4_\ ?BP_PIR>%O@#G_D&_"G_ +\6'^%?
MD-_Q#]_M#_\ 0.\*_P#@X'_Q%'_$/W^T/_T#O"O_ (.!_P#$5J\JP5O][7]?
M,(XVO_T#O[O^ ?NCX:M='M?"]G'X?73X]&CB M%T]4%L$[; GR[?IQ7\T_[<
MCM+^VK\9&;_H>-;Z^@OYP*_H0_8B^$>M?L^?L>>!?!WB".WCUSP_I$=G>""0
M21B5
\(^#]TW@W2+F\OKS3X!
MN=K.%F=W8=2QR23R37;2_#W]G
37/$'PYT>UM5N)?*B+_ &2W;YG[# /-?F_-_P $ /VAH_\ F&^$_P#P
M<#_XFO*P\8UZE1U\0X-2:2;>J[[G7).C1I^RIJ:<4VTMGV/UJE\ ?L^*-O\
M9?PKV^HCL:_/O]L/_@D=I/Q\_:4\3>+/"/Q0^&/AGP[K$D#6>F^>J?9!';Q1
MN,1G8-SH[
M>
M!_%"VL>O:"\2W:6THFB!DB29-K #=\CKGT/%?49+E5Y2^J8KFE9W2UTTULV?
M/9GC6DO;4>57T>VO:Z1_1;^Q%\*KCX&?LG^!_!\VL6/B"30=.6U_M"RD+V]R
M S$%&/5<$*/3'M3/%'AWX&WNNWTFK:?\,VU1KAVO&NHK$W!FW'>9-PW;]V=V
M>
[DD0LNWABC+D=CQ7Q&&P<*F-J4JU50Y6_>>EW?7J
M?9UL14A@Z
U
M_96#_P"@Q?U\SR?KE?\ Z!OZ^X_7JV\)? +=_P @_P"$^/7R+#_"O0?A#8>#
M]/\ #-Q'X)B\.PZ6UPS2C1DA6W,VU
O(S; T*-+FIUU4=UHOSW/4RC$5*DTITG!6>OZ'YX_\
M'%"L_P"W;I/_ &)]G_Z57M?'>K_"OQA\// _A/QXUCJ&GZ'X@>:XT;6("RHL
MUM.\+@.O*2QO$2!D-C:P]OL+_@XJE_XSRTG_ +%"R_\ 2J]K[D_X)+_!;PW\
M=O\ @DKX#\.^+-'L=
M@ X*'Y2,8P5%>#F7#6&S&D\;E+3;UE#SZV73T/=RWB'%8"LL/CT[;*3_ OW
M1]'_ /!SG/YFN_!MO^F.L_\ H5C7K?\ P;73%_V-_%W]W_A-;O\ ](+"OFG_
M (+O_M%>$?VH?"7P/\7>#=2M]4TG4+;63E2/,A?=8@QR+U212""I].,@@GZ;
M_P"#:R39^QGXN_['>[_](;"L
$I[_QQX#L?^)>Q,^I:9"G^
MI[M+$H_A[LHZ=1QD#].$W%LUYO\ M#?%WPS\*/ACJ6J>(;R&WL[>,[M_+2D]
M%5>[-T [_3FOQ#B#+J&)P\E6T4;M/JGWN?O_ ;GF,R_&P>$O+F:3BKM--[-
M'Y;?L+_MVWO[-.I2:+K$EU>>%+[<_E\R-82_WD']UL?,HZDY'.<\Y\8?BEXR
M_;Z^/-O;Z?9W%Q)=2K!&S':PYRS.WW1Q\S-T'3L*X'XDZS#\8/BYJU]X=
MT-K&WUBY>:TTVV0R&-5&YB%4?>(5F8 8!+8P!7;_ +$_[34/[,WQ5_M"\LH;
MK2=2"6]](L>ZXME#9$D9[@%LL/X@!W45^/8?,J]6M#!XF3]DI6YE?5+;5]#^
MJLPX=P>&PL\XP=)?6903Y6T^5M:NRZGZ7?L-?L/Z/^R=X&69ECU#Q-J2*U_?
M%?F)QGRDSR(U/0=2>3V ^C?]6OR_C7'_ M^(&D_$OP/9ZQH]Y#?:??1K)#+
M%(&5E/3']0>000>178(,K^%?NF6T*-&C&-%)1MHEM;O?JV?QYGF,Q>(Q4ZF+
M;
_:W2Q^2O_ <]G?-\%?KK?\K"LK_@WE^&7A7QYX#^)$GB30]!UB2U
MU*S6W;4+*&X,:F*0L%WJ2 3R<=>*U/\ @YY.RY^"N/76_P"5A7Q7^Q#^QC\9
M/VJ](\077PMU!;&UT6XBAU '67T_<[JS(<+][Y5/)Z5^[Y1A:=;AA0J5%33D
M_>>RL[_CL?S_ )M6FL]DXQ
/!_P .OVT[.U\&Z;H^EV=Y
MX9MKJ^@TX(L8NC
X(-?C=\9O@?XB_8I_:,M]-^,WAN'Q5J$UI%J?V9]6D
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M][/T1Y+A/Y(_
\1_
M\$_=)^)^@ZMIWC[0_#)T74M9&N-HFCK+]A%ZMI#:I<*2JF-A''(K(H*L9"Q.
M[.2OJ2BOSCZW4/T;^R:'8_F]_P""K./M2WDFJ2MI9D!\M],
M!Q9F/MM\D(#MXWA\_-NKVS]E?3O#,W[%VFW'Q*U#Q!'XBM]5N$\.06[J\TNC
MM%$T:_/D1P?:3<,A(R"Y*@HP-?L1\:?@9X)^*5I'=>)_#.BZ])IX,L#WEHDS
M0[
\YM2
QZ5\?/'
M/PA_:8^#7A'P'J?A?Q)X;T_PC<2OINK6=W'<75JD[!KC
/P-\:;K0]4'VC0?$5E
(Q,:-9*TDDI)6:M9):
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M?XB0/
_9Y_9KUV.^\4>)O$#1W2B6WT*TE$DTR;@I(P X7DG+. =K
M8R017;? 7]M/]GOX8:')X5\(V.J>$X;Z)XFU&[M%Y?81O>0,S%N ,D'G';)K
M\YP/AKFV-Q$,1B(MPC;9-JRZ+R/V7,/'KAC)
G[1?
M_!)#X6_ O0M/\0+\1O$EYH^K3-!;Z=%90_;G91EQN^ZJJ"N6(/WEX.
35]/?3+)9FL;9U:'S9%=EW)+-#MV*0V(2V0 -W]#9#[3*Z<:=*K)0;]Y+
M5M);I.]K>70_C3B/&/-J\JT5&4WK%O1)M]7?6Y]*_P#!(_X:?"WP)\"IF^&]
MC>6\DDZ0:S
,_L<_LJ:;^RK\.I-
M'T^ZN-0FU"X^V7EU* IDD**N% Z* HP.3R
[C,ZHU,GIX*+?-%W:L[??L>'@>'ZU/-98
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M2IT
M+O\ P4C_ ..5P7_$-#\-O^A^\
\@FMYF\9:M.$D0J2DEW))&V#V:-U8'H00
M1P:_HJ_9T^!=C^S;\$/#/@73;R\U"Q\,V2V,-Q<[?.E5>0S;0%SSV %>#_MH
M_P#!(#X4_MJ>-+KQ-JT>J>'?%EU'%'<:II
_!^I:7XHFU'POX=T[2KEXK13&TL%M'$Q4EN5W*<5WX_P"#C+X.
ME_\ D#^+O_ 1/_BJQA_P;1?#-7_Y'[QU^5I_\:I#_P &TGPS4_+X\\=?E:__
M !JO7J5.&9OG;E=W;T9YE'#YY2IJG%*T4DM5T-E_^#BSX.L=W]A^+O\ P%3_
M .*K\K_^"@/Q^TG]J3]KOQIX^T&&ZATOQ%+:O;QW*A95\NT@@.X#@?/&WX5^
MFR?\&T_PUW_\C]XZ^;VM/_C5=%\,/^#=7X.^"/%L>H:UK'B[Q9:Q[2+*]GCA
MA9@<@DQ(K$=BI.".M>AE>>Y#ECE6PO,YN+5FF[K1]=-T<6.R7-\?RTL0DHII
MW32UMY'T!_P2QT2ZT'_@GM\)8;A5623P];W('7]W*#*GXE77->8_$S_@NG\#
M_A1\1_$'A75&\6?VIX9U.XTJ\\K2@\?G02M$^QMXRNY&P<#(YK[&TC1+7P[I
M-KI]C;QVMG9Q+!##$@5(D4!550. !V KX$^,'_!O;\/?B_P#%;Q1XNO/&
MWC2UNO%6L7>L7$$ M?+ADN)WF94W1$[07(&23@
\7?^"H?_'*X+_B&E^&_P#T/GCK\[7_ .-4O_$-%\-_^A^\=?\ DK_\:KV/
M8\/_ ,\ON_X!X_M,\_E7X'>Q_P#!PQ^S^O7_ (3#_P %2_\ QROH[]C?]M#P
MG^W)\,]0\5>"_P"TO[-TW4GTJ47UN+>3SDBBD;"AFRNV9.<]
UKWZ'Y2
M_P#!Q-S^WAH^Y?F_X1&S_P#2J]K]%O\ @AA"H_X)?_#?_?U7_P!.MY5/]N7_
M ((^>#?V[/C#:^,O$'BCQ1HM]:Z7%I2PZ>(/)=$DED#'>C-N)E(ZXP!WS7N7
M['G[,6F_L<_L^:'\.]'U#4-4TWP^USY-U>!1/+Y]S+
""#@BOR[_ ."G'_!"F/Q'
2:;>PW5G<6,[QRVEPC1O;R@A7#(V"K
MY0!@0#\H!Z
>%_$4
$
M?#^K:QKEGJFKOK$D^H>7YJ2/!!"4'EJHVA8%(XSEC[5]IQ/QAALTP$:48N-2
MZ;5M--[,^/R#A.O@<
E_$_XCZ7\*O!]]KFN74-CI^FQF::
M>8[511_,GH ,DD@ $G%?D)^V=^UQJW[8/Q.CM]/AO(]!MY_(TO3E4M+
:AKVI0J$MC?B,K:'G
E+&5KSJI-1C9V3[MF#
M_P $]/\ @G[IWP9\$KK_ (ELX[KQ5JR9D\P!OL,3<^4GOC&XCJ>.@KQS_@I'
M_P $Y&\/3WWCCP/8L;=MUQJ.GPIU/5I8E'YLHZ]1SD']*;:V^QIL7"JO JMJ
M>FQZG9R0S1^9'(I4@C((/:KQ'#&'J818?EM;9]4^]_,Y\#X@9C1S-Y@YN7,]
M8MNS5]K>70_&W]AO]NG5OV6?$JV-Y)<7W@_4),W=GG
K:QH<>I2^<]I9M%Y,;GEBNY"1N.3C.!GC%>L?L??L7Q_LB
MVFH6>E^*M>U32;X;S87HB\F&7(S*FU058@$$ X/!(R!6?#F#Q^$;I5K2@KI.
MZNK;:;V9W<
3FX^"N[Y>=9_]L*\:
M_P""-O\ P4<^'O["OA7QI9^-EUKSO$5[;3VW]GV8N%VQHZMN)9<'+#'7.:_3
M?_@H+_P3*\,_\%#G\)MXB\0:]H?_ B/VO[/_9PB_?\ VCR=V_S%;IY"XQC[
MQ]J^:S_P;2?#-F^7X@>//?BT_P#C5?O65YWEDLFCE^+DT[MNR?>ZMNC^9,VR
M/'PS*6+PJ3VM=K71)Z';_P#$0_\ /\ N^,/_!2/_CE(W_!Q!\ R/N^,O_!2
M/_CE<7_Q#/\ PW_Z'SQY_P!]6G_QFC_B&<^&O_0^>//^^K3_ .,UYWL>'_\
MGY+[O^ =/_"]_*OP/@?_ (*U?MH^&_VX/VDM-\2>%;74(=%TG1(=+CDO(A%-
M/()IY7;:"=JCS0HY.=I/&0*_5[_@B+:36'_!,/X?K/#)'YC:G(BN"#M;4[HJ
M?H0<@]P0:X?X7?\ !O3\$_ FHQW&M3>(O%S0R"14O;GR8R0<@,L00,.Q!X(Z
MU]R>%?"&F^"/#-CHNCV-OINEZ7;I:VEK"@2*WB0!515' &*>>9YA*F$IX+
M")\D'>[W_ICR;A_$TZT\3B&E*2:LM=7;Y'\U/[=_R_MN?%X?]3GK'_I;-7]
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M-+F"K<28Y
/C_@VB^&K1_P#(_>.MOTM/_C5>_C,ZR;,<
M/26+
3A
.?RM/_C5+_Q#0_#G
M_H?O''Y6G_QFO-]EPY_-+[F=_-G_ &7X'PS_ ,%=/VU?"?[
XAAU#QA=W
M%K(Z%5N8Q9V49=/[R^8CKD?Q(PZ@U6\'?\&WOPCT/6H;C5O$WC37K53EK26>
M*W5_^!1JK#\#7W/\$/@[X=_9^^%VC^#_ KIL.DZ#H8*> A@,'=QB[W:M9:Z>8^'\AQE/&O&8JR;3T3O=NWW'<4
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M:< I([(<].1QFOY\?B#\4_$'Q2\:7WB+7M6N[[6-0E\Z68G8%.T *BKA455
M554!5154 "OUI<1/B"E+#T&X**5V]7Z))[.VI^&X/PSJ9%B8U<0U+5V2;M?
M35NWW(_62YMIK&ZDMYHY(9K=VCDCD!5HV4X*D'D$'@CM70?"SP[>>+/'.FVU
MG#-)Y=PD\SKG]S&C*SN3_#@>O5MH')%9_P#P3D\76/Q+_P""9VJ?$CXK:+J&
MJ-\/_P"U'BU-?,2_UK3[.%9M^\NHF9")8%)8*/("G!#&OC70?^"U?Q(\$?$>
M;4-!T/PGI?A>1C$V@BR\P/%N8J9+IO\ 2'D"M][>$SR$ ^6OGZ-3$8Q3P]""
M
)-6D::\U:
MX:;8[,ZPH?N1+DY"(N% ]!7.KG;72>,O!5QH>G:+KT-C=0^&?%UC'J^AW$I$
MBRV\BAQ$S@!3-%NV2#@AES]UE9N=1&ED554LS$!0!DDGH,5^E97C,!#!15XK
ME232M96W3\^Y^!YK@
\?#OXX^/K7]D;7-'\/W&I1Q
M^%]8M))+NVRTUI93QW#,@< F.,2P(2PQ_K&4G:2*]T_8 ^!=C^V/X5NM8^,7
MA>U\;6.@W<8\-ZCK4'GRMD.MQ$KMDO"I6/Y>5#;NZG'I?_!+_P#90U+X.?"S
M4-6\26
%IU Z45\*?M@48Q110 4444 &**** "BBB@ HHHH ,9HHHH ****
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04 %%%% !1110 4444 ?_V0$!
end
EX-101.SCH
4
rgnx-20260824.xsd
XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
100000 - Document - Document And Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
Cover [Abstract]
Amendment Flag
City Area Code
Document Period End Date
Document Type
Entity Address, Address Line One
Entity Address, City or Town
Entity Address, Postal Zip Code
Entity Address, State or Province
Entity Central Index Key
Entity Emerging Growth Company
Entity File Number
Entity Incorporation, State or Country Code
Entity Information, Former Legal or Registered Name
Entity Registrant Name
Entity Tax Identification Number
Local Phone Number
Pre-commencement Issuer Tender Offer
Pre-commencement Tender Offer
Title of 12(b) Security
Security Exchange Name
Soliciting Material
Trading Symbol
Written Communications
XML
6
R1.htm
IDEA: XBRL DOCUMENT
Document And Entity Information
Aug. 24, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 24, 2026
Entity Registrant Name
REGENXBIO Inc.
Entity Central Index Key
0001590877
Entity Emerging Growth Company
false
Entity File Number
001-37553
Entity Incorporation, State or Country Code
DE
Entity Tax Identification Number
47-1851754
Entity Address, Address Line One
9804 Medical Center Drive
Entity Address, City or Town
Rockville
Entity Address, State or Province
MD
Entity Address, Postal Zip Code
20850
City Area Code
240
Local Phone Number
552-8181
Entity Information, Former Legal or Registered Name
N/A
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, par value $0.0001 per share
Trading Symbol
RGNX
Security Exchange Name
NASDAQ
XML
7
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
.report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
.report table.authRefData a {
display: block;
font-weight: bold;
}
.report table.authRefData p {
margin-top: 0px;
}
.report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
.report table.authRefData .hide a:hover {
background-color: #2F4497;
}
.report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
.report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
.pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
.report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
.report hr {
border: 1px solid #acf;
}
/* Top labels */
.report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
.report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
.report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
.report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
.report td.pl div.a {
width: 200px;
}
.report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
.report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
.report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
.report .re, .report .reu {
background-color: #def;
}
.report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
.report .ro, .report .rou {
background-color: white;
}
.report .rou td {
border-bottom: 1px solid black;
}
.report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
.report .fn {
white-space: nowrap;
}
/* styles for numeric types */
.report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
.report .nump {
padding-left: 2em;
}
.report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
.report .text {
text-align: left;
white-space: normal;
}
.report .text .big {
margin-bottom: 1em;
width: 17em;
}
.report .text .more {
display: none;
}
.report .text .note {
font-style: italic;
font-weight: bold;
}
.report .text .small {
width: 10em;
}
.report sup {
font-style: italic;
}
.report .outerFootnotes {
font-size: 1em;
}
XML
8
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
10
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.26.1
html
1
23
1
false
0
0
false
0
false
false
R1.htm
100000 - Document - Document And Entity Information
Sheet
http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation
Document And Entity Information
Cover
1
false
false
All Reports
Book
All Reports
rgnx-20260824.htm
rgnx-20260824.xsd
http://xbrl.sec.gov/dei/2026
false
false
JSON
12
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"version": "2.2",
"instance": {
"rgnx-20260824.htm": {
"nsprefix": "rgnx",
"nsuri": "http://regenxbio.com/20260824",
"dts": {
"inline": {
"local": [
"rgnx-20260824.htm"
]
},
"schema": {
"local": [
"rgnx-20260824.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
"https://xbrl.sec.gov/country/2026/country-2026.xsd",
"https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
"https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
]
}
},
"keyStandard": 23,
"keyCustom": 0,
"axisStandard": 0,
"axisCustom": 0,
"memberStandard": 0,
"memberCustom": 0,
"hidden": {
"total": 2,
"http://xbrl.sec.gov/dei/2026": 2
},
"contextCount": 1,
"entityCount": 1,
"segmentCount": 0,
"elementCount": 24,
"unitCount": 0,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2026": 23
},
"report": {
"R1": {
"role": "http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation",
"longName": "100000 - Document - Document And Entity Information",
"shortName": "Document And Entity Information",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "C_0d12f8e1-1fdd-451c-a398-267633c7b1e8",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"h2",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "rgnx-20260824.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "C_0d12f8e1-1fdd-451c-a398-267633c7b1e8",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"h2",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "rgnx-20260824.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "AmendmentFlag",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CityAreaCode",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"label": "Cover [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentType",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityFileNumber",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityInformationFormerLegalOrRegisteredName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityInformationFormerLegalOrRegisteredName",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Information, Former Legal or Registered Name",
"documentation": "Former Legal or Registered Name of an entity"
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityRegistrantName",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "LocalPhoneNumber",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"dei_PreCommencementIssuerTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementIssuerTenderOffer",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Issuer Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
}
}
},
"auth_ref": [
"r3"
]
},
"dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementTenderOffer",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
}
}
},
"auth_ref": [
"r5"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "Security12bTitle",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r0"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SecurityExchangeName",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_SolicitingMaterial": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SolicitingMaterial",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Soliciting Material",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
}
}
},
"auth_ref": [
"r4"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "TradingSymbol",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"dei_WrittenCommunications": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "WrittenCommunications",
"presentation": [
"http://regenxbio.com/20260824/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Written Communications",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
}
}
},
"auth_ref": [
"r6"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r1": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r2": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r3": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "13e",
"Subsection": "4c"
},
"r4": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14a",
"Subsection": "12"
},
"r5": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14d",
"Subsection": "2b"
},
"r6": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "425"
}
}
}
ZIP
13
0001193125-26-363786-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001193125-26-363786-xbrl.zip
M4$L#!!0 ( (:J&%W.9T^AMA0 ^\ 1
"TR,#(V,#@R-"YH
M=&WM/6M3XSBVG^_\"BUS=X:NBQ*_'X'N+9I'3W:Z@2+,W:[[94JVY$2+8V=D
M!Y+]]?=(MO. 0!(2(#2AIJ9C6X^CH_/6D73PCT$W1C=,9#Q-/OZJU[1?$4O"
ME/*D_?'7P]91L_GK/S[]=/ WC-'Q:?,,G;%;=!CF_(8=\RR,TZPO&-IM??N
MFDG,$X:^?[[\BH[3L-]E28XPZN1YKU&OW][>UFC$DRR-^SGTE=7"M%M'&)>-
M'PE&Y'MT3'*&&H9F.%CSL&%=Z4[#M!JZ53-TT_P?36MHVD2UM#<4O-W)T6[X
M
2L#AF0W3*$Y*$G,2H5?6Z!V"&-708Q^A25LO0)
\'!V-9J+>C[LL3H4Q$E1<@15QF?!!"/0Z]^_?6V%'=8E
M^.[0*;N#_8R%M79Z4X
=HS3)@>WP%:!X!X7%T\>=G WRNJ+:
MNFRT7K9Z$*1TB+)\&+./.SU")=,WO-Y@OTM$FR<-TL_3O_%N+Q6 \7S_/X![
MR@8-;1_?LN":YUBVBS/^'X8)_7<_RQNZIOU]OY=F7 Z[(5A,I*38WU'04GY3
M=49YUHO)4)*+_'K !PT)$Q/%3TXI2]3/,3TA3C_NG/X9ZJ;-]-#'1F1[V-)U
MA@,7YL?W;=L)"?-,"P@J(5W9"^.-0Q!#5(JBTYBT2Y0,\DL6 ;+^U*AN1![3
ML1Y1BBU;#S$Q?9 ZCNN89N@&.O-V/D4DSMA!?0J:V
2V]<\U[T':7T:
MI8)%3(",9]FG \GIC4PQ%O2&%.
I=1TA@)-7BBCYK@XP"
M/:GF)]M4CUG:%^I)2;)&.2*%ID5'5%9E"D?5$Z?R.>),( 4VF\G.1\W?IS%R
MM_*GZM5TZSU 6$JK)Y S(I?JZ--8&U7UQM]&8-('BE9?JN>JD_H4:BH\CA!7
MG^").K#.71:JN-'8[_($=YC49@VM9O-D)@-.MQ'&) ,%UR50M902ZE]X9F+G
M;A?V[!9[5;D@%0 FSM->PZ@9=B]'-.T',4,_:^IO/X*FE9P ='+2_&BRI??
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M7!?-E\Q5/2L:0F!%
#9V&3=7'%Z?OD-S:+P
M)7K;F6UK^,3SO8 2,"HC'5N!IH,19D=8#T@(>C2*PL!XDBDQ89]4;IPR)S=4
M\"B3N*2ONX9/^;IC;/GT&?29OV'*;'UB'Q37Y
41BCO,/FI+\!@A%Y.!F&')&TF@T;R
ML^Z;U@1"P2 %WY9(8W':F)3#D^ V
4!23
M7L8:&>L1 ?9VX73*UD75] W/>,!C,/@;5?&J%!2C([:KFI>-#R0.)2"5F0RO
M]I4;+2N!HW^OE](45V1Q"\#A0#!RW5#_Q_+%[ F\+PON 5:ZZ(5PJFFZ-/7+
M5TJ<:?#BAHF
D]84(
M6$47@0POF8QJH-WJF1'PQ5B6(W8CPY9"?6;T0V-*>\_6Q,2SJ44##3-&76PY
MX &.K'!_X]"0C4WM'6R+DU\H9S'D\*EW$%%B.GC#A_D#0IO
%,.'_78?\&A8>RH<.T\W@TRMY_0..\$/R?1/TMK+NECO3V^_*Y][
MW3;*N"O#>IKA;OH.<4SB8$/7";8(,3 QC!#;NF5J1(L\3]=7%1=%8/&2M7DF
M0]'Y&7Q9JTTQ=_"+S^OER9>3L^^?F^=J:68!>;' M)N;99JZM7ETN#BZ=D\&
M!$PI.=>%(JOF&)$,M7HLE %.BGB"FGF&CCH$])CXL&+(8EE3?RM4WZI0W5R#
MW)AOC\^PXI]0YVD=>4^H9,T'[Z5<#,"_I(&/.^;.6W4W'A3B#YCMC+@:V.
CUE,;HE@RYCM;]E%79)F=-NTB
@1HL%^N>K;NV]20W?H;*
9WUVEC&3X]CSO,('^V1<\HUS%==7B+#@84\KKPP;R_QN?@J.T
MV^693+]$4N:C@LVWB%X[HIN7+732[<7ID E%W-/B%9VEM=E8GRG/WG=D?^Y<
M/CQ[3W3!-X0'MFC;HFV+MBW:G@=MVV#/<_EM5FAYIN?Z6
UF4L]!Q-B!M@R",-$
PB!2Z*_X_WU)+52W*0H7FV
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M@^+*^S9JYG8_W-P-V\LBZ
[5E#7N[ B?4AX*C#PFNU!YOT>B+M"2X3_$ O
MH(#%Z:TD-OE1TB#R\.\H I4#UC'/$)=-4"#"/$49[_;CG"0L[6?Q$&4@C+)H
MJ&J6%=( AE[D395[OL5X(U(?VA&(),/J6P0:+;V5]608GLMDMVPE.WS=:$.3
M)#-QR)*:97D(4I(WL&$IJ3"EU
+6GC3/&3SKK[]UX\N EQ+@X>V(1H
M.:YMF ;#OJV;V/("BKV@V ;A.D'D@5^R
1 IJL,])>??=>R]N=IJLVANA)!@.9)#*'>Q"$+EWVP/BW#+GGJSN$*
M\DR%7=U%1Z>7R#"U&A0<:PQYWM>*M.R\"5HV?=_RB69CU[.!@AU/PQZS7$SM
M@ 2&&;+0#5>EY18HP!"0GK2_@4 %J1IO"7E,R&/LH&Z)GOM4K%L$Z\8$(4\=
M#3(B8PN\!U7R'5*R:SA4=P,/:[H#E.QY(?9,U\,N"&@#*%GW5H]!7 @F);(\
MK%$=[225OCB/(GGNWY:B1P?=0.OA!)KFRFC=HMC8#3XL1M]%V7=(X
C1R5I*H)0^%""W\2:"D^93=L(_99^^
M;K]01];\CM[L26!WPSW&*-SSVG'8EPEMJIU@5_)$]>(8L+!3'([\@LD3#T\!
M^CE2?YJY3=_;$O?RQ'TEB!QD<1SSL NU=U\TFVI+V5O*?D:Q?5:>@:6D-JNL
M4#"
SK
2B32BN\1@!#NV[F/+)#8F%/@C"&UJDB#R77_E)(/2)BC,@>?D
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M) /W0'C1)Y%S! [EDOERC?!7D1<[)'0,K6(,>:P]20E5K!_4: ?%9"__D+*
MNZ*?9O2(:-H#@313SO%[Z5D=D&)*DX 42U*UXM#/F"H% R^3P.0%ENK*-U3<
M5R>G6O45#V7GMQRZEL2;P$#@BV W/(-ZT>C*51*&\I!365A>V$F)H%F1_D4?
M6NXP=\EHN6-2VM4689'EZ.DY#G6>CLG,O@EO@S,E'[]D,(K9 %,NBKF2RT#]
M;K)?W>,IO]Z_AU!>"
2"0_9?EZS=CXNLV=-C-+Y >R7K[-GAGVVN3::H.#7'<1_+0W=^# U\GJ [
MU]OLH>GK*]"N5%[2'#>T_=),4D_Z_@?0EPFHQ%"JUPX!5T/>,Q0RD =T.NT"
M12+M*BWX1ZU50Z
((R@2@7;MXL6/%;@[2$29RFZ3M+;1#I4
MO_75&56M84)AV&P/W<)+T"H23P!."")>G675 0)7:+@[/-"Q,)_2DF&#GG20
MP:80+.L'75Z4JR#^S(%NVCS,T%<>L@1&=S@Q[@K:SU_'F 0G3S:0, *.(A/=
M&D*',%>]469[3YU? '*=263!V*,^T%'6 =B)=-DZ/ @?+^F2ZB42W;4%T)F
MVI174$E94&7CR]&I5/SJR%UH!GQ4!F" 43>Z9+GVFF)U(U3(4L+G5;3*NI$A
MHT%\O#.LN-^EU"LC;_\ATI+TK/G[!8%-$27)
!@+6_G?)YS$G16+2*!\-9$-6 +,'XQ#EB/CD@*;X:Y*Q)%:E0"DWN3R8
M
Y&MH\J\XO?Q$7MV7S<;6^Q,8LVR52:6YO#$")L9+
MFA;*:'A&8^#KX7WUON6T*4[S[W':Z2B^HX[=DRG#V:16>8#]UL-K:D5B0]E-
MWGX[_JNP\6C"[N0V7A6^6%L&[U0>OZJW8D[O2Z7T^JM=B.4];];.^M*U[N^I
M7G3)U=L 5?6TE*W*[CQ+:\LM93\+VI=./WR[B$<;@.YW0^7'+ L%[ZD;=);-
M.G3480N;*<$V(H]FK?D5TO]]*<[X\;#W8D+EU5!'4$?()7/13@:8#7S_3[W6
MR;L/(S6*'F%2RL+R#JV&"BO(A:LR87MQI%],11NIBE_<
V767UXDP395#@[Z_OGRZVR__EV?(?JNQKK-(-NT#+)E2*L\!O$-':31
M_')V>/7'Y4GK&1GN/E8V:=7A8B*-MLCR_:L/'%8LRRRZ$#\C/9CVXR$*23]3
MRX-<^IQ*#4 W ;BM@(9B/4XNY@6L0^)(KF7+AI1S6Q:0.07]!.JHYH"_.JD
M!-#:H\LBFW*.B?.4DT*LIU1Z2IWYT&WW-V^W[&V1MD7:IB#-JIE+94L4Y5]U
M,6
67[?X
M7!&?GX?/?T';DNL%FW90VV9/8#VKHPN2"QY>HW_6T%%'\"SOD@PUFUNM\(:T
M]19I6Z2]2Z35W.4.'U_K L%B4?\'Q*L\$W-\>_;_\I AF3'&Y:ZG/2C*681:
M
#*2K @ +EA 1
"TR,#(V,#@R-"YX
U5>ETTYU.4T@,1 LVYR0M_/=G.W'>
M< *%)@'$/JQI\O/CY_%;[*=V+C[/IPYX@L2U,>HHS8:N (A,;-EHW%&^#=3N
MH-?O*Y\O?[GX557!U77_%MS"9] U/?L)7MFNZ6#7)Q"\'7Q]![[__G #!N8$
M3@UPA4U_"I$'5##QO%E;TYZ?GQO6R$8N=GR/9N
M!.V6WOJ@ZI_4UNEC\T/[Y+3=/&V
FN\ 2T7S
M1@@Z#ER :QL9R+0-!PQ$KN]!'YD-T'4<\,"2N> !NI \0:L1@,Y=J^T&(CR#
MC*%W:TRA.S-,V%%"*02.(9H/;
1^RA[\%K3*97<&3XCM=1
M?/2?;SCVR(86+5T'LF))!20>T^I ;ALB?]J*
D;;Y4%F')-<_/SS7^5+G\!0#>1.SI#!,/!"WE
M!IN\&@HR8[^I(D>5W5*;+?6DV:!@"D!+;:R KK8="5&E&Y&(VL.F)$0EL=S/
M\O*5UNI:.;HBM;1A:M#Q7'%'97?R&,C;]
&E$EQ0,!&@@
M 7>A94$R\+X+K3MTR:]GA([P*"BX&WHC3!R&%"0T#
GBVGE)@MOBGI*
MUY[H9+R(G7#4R5;O QR56;M\N&M/"!QU%#8\JP*--=XWZ]=[".11D1W%I=W&
M"<>.E&!C"!U65F$TXUDP"'$9?#@6Z+;'$D0PZ5SY*].BK]
,J)LE&C@)N_'%%E(*.
MW[4L.M:ZX0_:$V%3PB\_M@ZRK)7=D4?\C%9134360?0>T_F?\[<]R^DN!<%U
MT!W0%RZ\(_<$/]G!)+N0<#:\4LH]VEN(X?3I6V+^)USD
G"
M_ ^"G[U)#T]G!LJG*H^NE/"U[
#_NT
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M RD3++25?N&K".',@ #%(W_Z:H*_FQEORUMAE$FU]Q5_H;$0Q,X1'HO+@##
M!'>H.BVQ#?!*2GC[QP0PR,I4I R"5Q(28 (*6GI/+O(.7DD-1V7U(G#+UY/Q
M%[83$H(!C@8H7/G\I:;#=BH$) @P00A:OI;8FMA. ,,! 5#YI L=BNUTI* 3
MO2/,H*(>OYYQL:W2*(_W(,@%\&R8W#@CP'(J7W':[]A.68Q5$?D< V0[%104
MI%$KZ%]9HV1#"1P&<)P*2*^R3#8406%5,X$+ F 0( ,.7:&L$@15I23KO&S(
MGZ<%> 2:K;?#=T"@5L$\:
R
M'1TB.YQG/^4Y7%50E>X#$527G:
G(G
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M4:X3D;
U-D7OF9T
M.
Z\I9T<<5USH0@8$;$.O2]UQ7
M@:40BSP_))%)*R+N@ =5CQD3(U:Y[[VPV/N(=>[[:R+',(E[Y.E!",PQ6V*9
M9P
6I<-M4A;:]]G=W)'+M)WLN^]46;G
MQ2USWR<"&3
M2'SP.[@3?'#\\G]02P,$% @ AJH8720,]R6M$P (%H \ !R9VYX
M+65X.3E?,2YH=&WM7&MSVT:R_9Y?,>O4)E)=DA8E/V)*<5U:#UL52_**2NS:
M+[<&P) <"\# ,P IYM??TST#$*1E>[.Q(Z^76Y6U ,RCIZ
/"W;E<<
MG9R>BV%
O%)KLONMVG!S3@H5627HLC62HQV-W9?=3=^:F[^^"J_VBP]V#0
M?]#;[>\]^9^=G<'.SK*7*1963Z:EV(JW!77"S'FNTE0MQ(G.91YKF8I1/6='
MG.9Q3PS35%Q2-R
C?G=P;3,TJ??B8.ID@G^%0>E+E/U]/A-]\F3
M7O_@OG]$@_NAQ4%DDH5PY2)5/]\K9)+H?#+XJ;C9SZ2=Z'P@J]+\36>%L:7,
MR_W?NSI/U,U@9[\[5]&U+KNENBF[3O^NNC)Y6[ERT-_9^?M^89PFB@=6I9*X
MO'^/R4GT;&VR;FF*P4[OH
:&)B5B(V,39;MX
M@SD.BGKXL
0ON@'$
M
UM,[@F9EK=_"'1Y]NSV=R'D0<;V
M'A
B&&>FRJ/%5G.206Q-78A?BT2LMJPWI?/WW3[NWTQ-E:<
MO1J)T]-;^=:V 8]ZCQX]_ONZVGY.
6V%?ZKHO*9)./B\)??3E^^/.Z(
MLZ37$<-J B
M\IERI)XP1X-$G*E>BG"JL9M%II&XK3E6F$V?X
"JM3F"1G2@7A8+DBBTOP>@L
M4V?$=6[FN9!.O*A(1<5HD2?69*HGKC#NK[U13YP80\0GXLA6$S%,P#7M2NN1
MS=;)T7!;%"FV HW@+? QQEJF4-95W4E3,P?GF=X$\ I+@):!7ND660$IP("Q
M< 7\BCB[/!6 500%B$WX>Z8$UHT6N@#DX)
M('JN*F"FEI+TN
C8B9<:AMPI,2R*%%SS O#L)00@;$>N) 12V:QWE\9B
M8PX_]WK)W,7[KY6(5*K5C*T4Y*!148DXJ
51O?4Y!,@=A*>8"RZ5<$M*"0(%A+64^*=A'$CDV9@.YQRCF4O
M@GDDNJUVUS3%6*>*S$L0XXY?1;(OG-2).*RLA4$>(8IQ)N^(5Q!]6&FPF*8\
M/+[@KK6N]$2+!U81& :1<>44&SE:Y%$53Q6BM+"H4C.]VBD)1L5XJ
; 9"9Z/%:69HYE 1K\ *9"8[:.*_86W74Y93WSK((6$C=*XH$L
M>2- $%K'UQUH99Q626UT8:1!7R)8Q9TCY<7X]*6A';J,%V#MNPK&%GM&M%"+
MN2K%\.P(+(?FHV&A9Z9<;HB'3^R @B48@R<@-(S3JYG_%=C!C67Z=BP3Y3S>
MQP;T7>>P13 0B8'LHE4-3-(%R_14HE.B,I.S9I$: PK@,]8A(ZAFN:#>L Y
M;UZPH2ZYJJR)S237%-CR0/PJ4AA/&_0/!HDZ. ^A&ALYAY(+-C%ZK,DX3J'D
MDRG!0CA@C(5WA'M DT8 0EI+&MLA(E(F 0VB1
Z).!<60[FAFX]_M[.Y\22HD5/H" G P=C"-D
M!
:-!H(((@/>*Q0HJTWEO+V6B4=)9(E;3G+!%CG5US0K/!34AKE.HD#@:[E'
M(+Z0Y=1#+3PK"AJP+S0?!'JL8>P98LF2LI)H'LO*>0P6S/C[V+DGSDW8/L]Y
M1QTS%M+W!-+0'B]"<]J!WL9:;ZSU9USO,T4BVY93[0.0W-B,33/:)E5,5JK.
MM4 4&Q4IH.RP!"S\)
2A7D!5),"ULTX268/)TL0F?OB&QKT.'9V;A:O@.T) ;LO?8>)^0X2C<:B^Z
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MJ!-IX()QV$E$A/GO"[C+T]T1M$9ZI3*4/@"7JJQ&IO!ZDW01&X
-%/1VWZ:H\N;W^H9E]:M=.BW5.^=2N*V&GN:YF?_4#AO2O
M"SE1W<@J>=V58XC90*9SN7#_G24TGQ*=SU
(@!(AEI, :2
M2ZFLO/+I7D07]2D&C>L[AE-H,L ^#9K)M\92VI=.T'U$UM##V6*'B,C2P8;-
M7)UQ:V(F'M.;3"4M9ET-U\ XA2 L!W$A/,I4V1$1?-UJPP1BP9&:)0M/U!
G2?,#A\
M5\DZ^8>NM;.E0ZJCW=$C+)MRF0H^8DI% IS4L#Z-W(ICE_EPB*)&'%;*4)8X
MA?*FI, ZS&<-PE/I6G4"[%=2P%%:84,UN%LOA;E.VQ).HB"
+*XC)4_L6@*2\4FMRNH&'',$/NKIH=RNM%7,
MR57X+W^"1@D-REGP20;%:!N_]%7XI<]4$!JD@1!1<_I\80L"GEP5^
2%>**RK+821SJ4AG+(< /BE-1V+#9.:/XJ^"=]BZ
M/!M>;0?K[V&5&%OC3X(_79SIJZ?"F+7'R?QL?)[&1#NQ-;PZ>[7M@QD^)>/>
MS43'T,E"8:DUH4X,)Y2CV!P0;]3LR\*_9Q>_7JU56=^]S#'4:VABL(?8I53Q
M-*?R#3K&]DEX4D%1U]HMRXD$X8K&[7@D4@5;4!B:A.YW42*OA11[8J0I24YQ
MU)@BVA!1[^[L/.FT6$0FJL!\"L&J=Y*([Z@6>RR&P]_6AEQ=!5L*3OP+BO$H
M*36A4K]"<
#Q!O*7QT[8PC&='=G=W;(6]=@K@O'%@1>8!/
M;/0 'R;JV;/?NC3$7O_!]NUCU$6*1 @,<*1\G B*^*AUT>'
O<2+.?/SK>[0+[2 F+U8,8X^JS%GH^-S,JL'(_
MBG]>O$3WT=EP4TS_"3IZ*YS^2(!'Z2C>*R[ ;72;4BG #A/_?BX78JID6DYC
MZ0O#0H@73NI!8LJNGR1 F2)5Y/>M3W[IG#8X% ?[LVDQTTZ7*_'*O^JWOI =
MIWNRRV)JF,?&I]WY3F[PPS>,'TXN+E\/+X^Z+R\N?CD]?RY&5\.KX[/C\ZNO
M(&HF%''%Y6448'(:E'0WE-XZ\P\PG)U+FW01YUZ3L:;D*M<"NPY_KZ-N
M,B,9(#H7D(W%*(2XNX^'=?8"KRJK2S)(0U^'TW^RM]?A="P&3.C8G;Q7T[5_
M?$O7XYM@MY9C/&B/P;ET2MLV=-81-($D*BL:=\)]HW!
4VS<=&
MG+R//9;2_H!T;FP2;CJ D3/%M^O>*E\Q6'%AK)KQK!@7\3PZ@V@';$$T,L="
M;5-@'_]_)A?M1RII:#^3;:=SBO:[NKJO_8YRZ52FO-H2(565K;SQT5S[#7,@
M69F36;0Z8Y6N-.'B\/9S[5U67EH*V58&
>TPO_##:"[0 (.D2?
ME*PA=OJ=\)^=A@)(6^\T_PZ"KWW_H/368MY^Y8_$^%0;(L6'%(:+QTG")ZZS
MXG/#;B,NM?5Q0U-84M>&QH:JL;D.5+JI&*=FWEM#RE$HY>(*[P]3&RYL0@WX
M+*8EP'Y\WN2B]
_5HRO[JFAUE8U74.2I?OA<6
M!C&AA04ZJ%Q6+V?U9"U5H76TY%A)?5&:"VP=RY@K5I>T!=WP=6Q<,5_0QH<*
M6Q^H:!M7&5A#UZ5[XH69TP$-W6I2OM _+BM06A<+,!1OD>'KA:B>':#E?
)M!6MC"<9'FO2U=MI=^_,-K46FUJ+3:W%W>>I
MU9CLM#_=8@]^2;=A3[QI\2Z=+ [_=08O-6$'!\M+/WA4^405-1C6=VQA9Y8_
M.718^YN0P_8V'DTN&C?LYW J;N#"2DZ"BS+0DWXZB+SJ";F!_D[WER9;0K>Q
M!&-)<:1BQ29^K\\_O/#0FTM&A%9&:5@B7_@=MY?XH>G_X6^C E=Z"ER;A'^T
M;3',.T,.;X.7V1:Z5-RJ(!D='S:@5
O
M>Z"O]_SBMZ\G%.>?L HQQT? &&.JYF[.2O#$M
A6*3WT'6?'5+M/#.4_(O
M9DF[:(]7VQ"J8L1(T"#K#]KI H/V]_76<0U:KL":)?9/N,*';C5%E&63=,N;
M1NYP9"(TX>>(\!-!=2Y_\4TZ_KI@W;E)&C6@+J9JEW>5XM^I(>!AZXL?_#L;
M#8BCB(HN(5:.3FJ
<=EO-9<%/_01@.K*VRU]12&O4-'HI5_JX(N
TR
M6X7;QG:W!T>;!.\WF. ]O#B_&AY>C09W+^R4SST"I 9*AKV,K^GYL+D6=6BR
MK,I#:86C;Q^C^.&CO;C_UW/S*/:D_Z^E\I2;2)OV6
+?BK]JK7D]/)V_?@:A?,O2\Y\:VF^@_MT#_WI
M=P?W^=>3_Q]02P$"% ,4 " "&JAA=SF=/H;84 /O $0
M @ $
"TR,#(V,#@R-"YH=&U02P$"% ,4 " "&JAA=Q'@R
MDJP( "Y80 $0 @ 'E%
"TR,#(V,#@R-"YX
"UE>#DY7S$N:'1M4$L%!@ # , NP )HQ $!
end
XML
14
rgnx-20260824_htm.xml
IDEA: XBRL DOCUMENT
0001590877
2026-08-24
2026-08-24
false
0001590877
8-K
2026-08-24
REGENXBIO Inc.
DE
001-37553
47-1851754
9804 Medical Center Drive
Rockville
MD
20850
240
552-8181
N/A
false
false
false
false
Common Stock, par value $0.0001 per share
RGNX
NASDAQ
false